96568-02-4

Usage

Chemical Properties

clear yellow liquid

Upstream product

• 82671-02-1 2,6-dichloro-5-fluoro-pyridine-3-carbonitrile 
• 113237-20-0 2,6-dichloro-5-fluoropyridine-3-carboxamide 
• 148874-68-4 methyl 2,6-dihydroxy-5-fluoronicotinate 
• 82671-03-2 ethyl 2,6-dichloro-5-fluoropyridine-3-carboxylate 
• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 

Downstream Products

• 96568-04-6 ethyl 3-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxopropanoate 
• 499241-14-4 8-benzoyl-6,7-dibenzyl-2-chloro-3-fluoro-5,6-dihydro-1,6-naphthyridin-5-one 
• 182868-12-8 C₂₀H₁₉ClN₂O₅ 
• 182868-14-0 C₂₀H₁₈Cl₂N₂O₄ 
• 182868-16-2 C₂₄H₂₅ClN₂O₆ 
• 182868-18-4 C₂₇H₂₉ClN₂O₇ 
• 182868-24-2 C₂₈H₂₉N₃O₆ 
• 182868-20-8 C₂₈H₃₀ClN₃O₆ 
• 182868-26-4 C₃₁H₂₇F₂N₃O₆ 
• 182868-22-0 C₃₁H₂₈ClF₂N₃O₆ 
• 100491-29-0 ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 
• 100490-99-1 ethyl-3,1-(2,4-difluoroanilino)-2-(2,6-dichloro-5-fluoronicotinyl) acrylate 
• 104051-69-6 7-(3'-aminopyrrolidinyl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride 
• 100491-30-3 ethyl 7-chloro-1-(4-fluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate 

Relevant academic research and scientific papers

Discovery of the decarboxylative biaise reaction and its application to the efficient synthesis of ethyl 2,6-dichloro-5-fluoronicotinoylacetate

An efficient synthesis of 2,6-dichloro-5-fluoronicotinoylacetate (1) has been accomplished in a single step using the unprecedented decarboxylative Biaise reaction of 3-cyano-2,6-dichloro-5-fluoropyridine (4) with potassium ethyl malonate in the presence of zinc chloride.

KRAS MUTANT PROTEIN INHIBITOR

Provided herein are a KRAS mutant protein inhibitor, as shown by formula (I), a composition containing the inhibitor and the use thereof.

Heterocyclic compound and application thereof

The invention relates to a heterocyclic compound and application thereof. The compound is a compound represented by a formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a hydrate thereof, or a solvate thereof, or a metabolite thereof, or a prodrug thereof, and R1-R2 and A, E, L and K groups are defined in the specification. The compound provided by the invention can be used for preparing medicines for treating and/or preventing cancers.

TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer. (I)

COVALENT RAS INHIBITORS AND USES THEREOF

The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.

KRAS MUTANT PROTEIN INHIBITORS

KRAS mutant protein inhibitors of formula (I), a composition containing the inhibit-ors and the use thereof.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) as follows: 5 wherein R1, R2, R3, R4, R5a, R5b, X and Y, are defined herein.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, X, and Y are defined herein.

NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.